Cardiology Today -- The agent is under review for treatment of type 2 diabetes. The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voted 10-2 that evidence of cardiovascular safety with saxagliptin is sufficient to rule out unacceptable, excess cardiovascular risk with the drug.
